Celltrion Allies With Rani As Exclusive Oral Ustekinumab Partner
Rani/Celltrion Suggest Potential To Broaden Partnership In Future
Having previously an agreement with BioFactura to assess the company’s proposed ustekinumab biosimilar with its RaniPill oral drug delivery technology, Rani has now unveiled a deal with Korean major Celltrion for use of its CT-P43 Stelara biosimilar candidate.
